

Knowledge Gaps in Vaccination Against Meningococcal Meningitis

Two national online consumer polls gauge the knowledge of and attitudes related to meningitis*

Meningococcal meningitis is a rare but aggressive bacterial infection that can be fatal or cause serious life-long disability within 24 hours of onset of symptoms.^{1,2}

Parents



42%

Less than half of parents say they have talked to their child about how the disease is spread³

38%

or its early symptoms³

83%


of parents report wanting their children to be immunized against all vaccine preventable serogroups of meningococcal disease³

Of those parents whose child has been vaccinated against meningococcal disease, 88% don't know which serogroups of bacteria their child is vaccinated against³



Five vaccine-preventable serogroups (A, C, W, Y and B) historically have caused the majority of cases in the U.S. Serogroup B accounts for about one-third of U.S. cases⁴

Teens/Young



49%



Less than half of young adults know that meningococcal disease can lead to serious health complications, which may include hospitalization, hearing loss or amputation⁵



Only 22% know that it is possible to die within 24 hours of onset of early symptoms⁵

In the U.S., teens/young adults are at greater risk for contracting the disease due to increased likelihood of being in community settings that promote close contact with people⁶

One in five survivors of meningococcal disease will have long-term consequences, including deafness, nervous system problems, brain damage or loss of limbs⁷

1 in 5

About one in 10 of people infected with meningococcal disease will die⁷

1 in 10

* The two online polls were conducted by Novartis Vaccines and Diagnostics, Inc. Effective March 2, 2015, GSK completed the purchase of Novartis' vaccines business (excluding its influenza vaccines business) in the U.S.

References:

- Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease – recommendations of the Advisory Committee on Immunization practices (ACIP). Morbidity and Mortality Weekly Report (MMWR). 2013; 62(2):1-13. Available at: <http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm>.
- Thompson, M.J. et al. Clinical recognition of meningococcal disease in children and adolescents. 2006. Lancet, 367: 397-403. Available at: [http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736\(06\)67932-4.pdf](http://www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(06)67932-4.pdf).
- Harris Poll. US Awareness Poll-Parents. February 2015.
- CDC. Epidemiology and Prevention of Vaccine-Preventable Diseases. Hamborsky J, et al, eds. 13th ed. Washington, DC: Public Health Foundation; 2015.
- Harris Poll. US Awareness Poll-Young Adults. February 2015.
- Centers for Disease Control and Prevention (CDC). Risk Factors. June 2015. Available at <http://www.cdc.gov/meningococcal/about/risk-factors.html>.
- Centers for Disease Control and Prevention. Meningococcal Disease: Technical and Clinical Information. <http://www.cdc.gov/meningococcal/clinical-info.html>. June 2015.